Federal Pharmaceutical (03933): UBT251 Injection Receives Implied Clinical Trial Approval for OSA Indication

Stock News02-03

Federal Pharmaceutical (03933) announced that on February 2, 2026, its wholly-owned subsidiary, Federal Biotech (Zhuhai Hengqin) Co., Ltd., obtained implied clinical trial approval from China's National Medical Products Administration for its self-developed Class 1 innovative drug, UBT251 injection, for the treatment of moderate to severe obstructive sleep apnea (OSA) comorbid with obesity, with the application acceptance number CXHL2501306. UBT251 injection is a multi-target polypeptide receptor agonist independently developed by Federal Biotech, which works by activating the glucagon-like peptide-1 (GLP-1) receptor, glucose-dependent insulinotropic polypeptide (GIP) receptor, and glucagon (GCG) receptor to lower blood sugar and inhibit weight gain. Weight-loss drugs represented by the GLP-1 class are expected to address the significant unmet clinical needs in the OSA treatment field. Furthermore, clinical Phase II studies for UBT251 injection's indications of overweight or obesity, type 2 diabetes, metabolic dysfunction-associated steatohepatitis, and chronic kidney disease have already been initiated in China. As China's first chemically synthesized new drug targeting the GLP-1/GIP/GCG triple receptors, UBT251 solidifies the company's prominent position in this class of drug research. Moving forward, the company will remain committed to the research and development of new products, with a strategic focus on enhancing its competitiveness and innovation within the biopharmaceutical industry, which is anticipated to generate greater returns for the company and its shareholders.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1178930497?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-03 18:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1178930497","market":"hk","top_or_hot":-1,"title":"Federal Pharmaceutical (03933): UBT251 Injection Receives Implied Clinical Trial Approval for OSA Indication","media":"Stock News","content":"<p>Federal Pharmaceutical (03933) announced that on February 2, 2026, its wholly-owned subsidiary, Federal Biotech (Zhuhai Hengqin) Co., Ltd., obtained implied clinical trial approval from China's National Medical Products Administration for its self-developed Class 1 innovative drug, UBT251 injection, for the treatment of moderate to severe obstructive sleep apnea (OSA) comorbid with obesity, with the application acceptance number CXHL2501306.\nUBT251 injection is a multi-target polypeptide receptor agonist independently developed by Federal Biotech, which works by activating the glucagon-like peptide-1 (GLP-1) receptor, glucose-dependent insulinotropic polypeptide (GIP) receptor, and glucagon (GCG) receptor to lower blood sugar and inhibit weight gain.\nWeight-loss drugs represented by the GLP-1 class are expected to address the significant unmet clinical needs in the OSA treatment field.\nFurthermore, clinical Phase II studies for UBT251 injection's indications of overweight or obesity, type 2 diabetes, metabolic dysfunction-associated steatohepatitis, and chronic kidney disease have already been initiated in China.\nAs China's first chemically synthesized new drug targeting the GLP-1/GIP/GCG triple receptors, UBT251 solidifies the company's prominent position in this class of drug research.\nMoving forward, the company will remain committed to the research and development of new products, with a strategic focus on enhancing its competitiveness and innovation within the biopharmaceutical industry, which is anticipated to generate greater returns for the company and its shareholders.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Federal Pharmaceutical (03933): UBT251 Injection Receives Implied Clinical Trial Approval for OSA Indication</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFederal Pharmaceutical (03933): UBT251 Injection Receives Implied Clinical Trial Approval for OSA Indication\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-02-03 18:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Federal Pharmaceutical (03933) announced that on February 2, 2026, its wholly-owned subsidiary, Federal Biotech (Zhuhai Hengqin) Co., Ltd., obtained implied clinical trial approval from China's National Medical Products Administration for its self-developed Class 1 innovative drug, UBT251 injection, for the treatment of moderate to severe obstructive sleep apnea (OSA) comorbid with obesity, with the application acceptance number CXHL2501306.\nUBT251 injection is a multi-target polypeptide receptor agonist independently developed by Federal Biotech, which works by activating the glucagon-like peptide-1 (GLP-1) receptor, glucose-dependent insulinotropic polypeptide (GIP) receptor, and glucagon (GCG) receptor to lower blood sugar and inhibit weight gain.\nWeight-loss drugs represented by the GLP-1 class are expected to address the significant unmet clinical needs in the OSA treatment field.\nFurthermore, clinical Phase II studies for UBT251 injection's indications of overweight or obesity, type 2 diabetes, metabolic dysfunction-associated steatohepatitis, and chronic kidney disease have already been initiated in China.\nAs China's first chemically synthesized new drug targeting the GLP-1/GIP/GCG triple receptors, UBT251 solidifies the company's prominent position in this class of drug research.\nMoving forward, the company will remain committed to the research and development of new products, with a strategic focus on enhancing its competitiveness and innovation within the biopharmaceutical industry, which is anticipated to generate greater returns for the company and its shareholders.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03933","symbol_name":"联邦制药","start_time":0,"source_url":"","article_id":"1178930497","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1178930497","pubTimestamp":1770115462,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Federal Pharmaceutical (03933) announced that on February 2, 2026, its wholly-owned subsidiary, Federal Biotech (Zhuhai Hengqin) Co., Ltd., obtained implied clinical trial approval from China's...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03933":"联邦制药","BK1191":"制药"},"translate_title":"联邦制药(03933)：UBT251注射液获OSA适应症默示临床试验批件","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03933":1},"content_text":"Federal Pharmaceutical (03933) announced that on February 2, 2026, its wholly-owned subsidiary, Federal Biotech (Zhuhai Hengqin) Co., Ltd., obtained implied clinical trial approval from China's National Medical Products Administration for its self-developed Class 1 innovative drug, UBT251 injection, for the treatment of moderate to severe obstructive sleep apnea (OSA) comorbid with obesity, with the application acceptance number CXHL2501306.\nUBT251 injection is a multi-target polypeptide receptor agonist independently developed by Federal Biotech, which works by activating the glucagon-like peptide-1 (GLP-1) receptor, glucose-dependent insulinotropic polypeptide (GIP) receptor, and glucagon (GCG) receptor to lower blood sugar and inhibit weight gain.\nWeight-loss drugs represented by the GLP-1 class are expected to address the significant unmet clinical needs in the OSA treatment field.\nFurthermore, clinical Phase II studies for UBT251 injection's indications of overweight or obesity, type 2 diabetes, metabolic dysfunction-associated steatohepatitis, and chronic kidney disease have already been initiated in China.\nAs China's first chemically synthesized new drug targeting the GLP-1/GIP/GCG triple receptors, UBT251 solidifies the company's prominent position in this class of drug research.\nMoving forward, the company will remain committed to the research and development of new products, with a strategic focus on enhancing its competitiveness and innovation within the biopharmaceutical industry, which is anticipated to generate greater returns for the company and its shareholders.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1178930497","isCrawlerRequest":true}